Skip to Main Content

Finding Balance in Iron Metabolism

April 28, 2022
  • 00:00Today's speaker is Karen Feinberg.
  • 00:03Doctor Finberg needs no
  • 00:06introduction introduction.
  • 00:08However, we have several new
  • 00:10members in the department,
  • 00:12so for their sake I will
  • 00:15introduce Doctor Finberg.
  • 00:17She's been at Yale for a long, long time.
  • 00:21She came to Yale to do her
  • 00:26undergraduate education and she
  • 00:29graduated BS Magna *** laude.
  • 00:32And then Doctor Feinberg stayed on to
  • 00:36do an MPhil, followed by an MD PhD.
  • 00:42She went on to Mass General Hospital to
  • 00:46do a residency in clinical pathology,
  • 00:50followed by a fellowship in
  • 00:53molecular genetic pathology at
  • 00:55Brigham and Women's Hospital.
  • 00:57So after that, however,
  • 00:59it looks like Doctor Feinberg's interest's
  • 01:02basic interest was in iron metabolism
  • 01:06and she did a research fellowship
  • 01:09at BWH and then she was recruited.
  • 01:13At Duke University,
  • 01:15where she spent another four years building
  • 01:19her research until thanks to Doctor Morrow,
  • 01:23Karen was recruited here at Yale in
  • 01:282013 to continue her research work.
  • 01:33Doctor Feinberg's track record
  • 01:36track record of Excellence was
  • 01:40established early on during her
  • 01:43undergraduate education when she was.
  • 01:47Became member of the Phi Beta Kappa Society
  • 01:52for Excellence in Humanities and in Arts.
  • 01:56But at Yale College,
  • 01:59she also became a member of
  • 02:02prestigious Honor Society,
  • 02:04Alpha Omega Alpha Society
  • 02:07for medical students.
  • 02:09She received a Yale MD PhD Alumni Award and
  • 02:13she received two Young Investigator Awards,
  • 02:17one in 2006 from the Association
  • 02:21of Molecular Pathology.
  • 02:23While she was still a fellow and.
  • 02:26Another in 2013 from International
  • 02:30BioWare and Society.
  • 02:33Doctor Finberg has been a Co
  • 02:37investigator on several grounds at Yale,
  • 02:40and I will not enumerate them.
  • 02:43She's currently associate director
  • 02:45of tumor Profiling Lab and she
  • 02:48plays a seminar where she played
  • 02:51a Seminole role in implementing
  • 02:55clinical next generation sequencing.
  • 02:58She is associate director
  • 03:00of Yale Molecular Genetic.
  • 03:03Pathology fellowship and assistant
  • 03:05Director of Education for the Yale,
  • 03:08MD, PhD program.
  • 03:10Her research focus is primarily primarily on
  • 03:14molecular basis of inherited iron disorders.
  • 03:19Mechanisms of systemic iron regulation,
  • 03:22and physiological consequences
  • 03:25of iron deficiency anemia.
  • 03:28So, with that I'll let Doctor
  • 03:31Feinberg start for those of you.
  • 03:33Who would have questions at
  • 03:35the end of the talk?
  • 03:37Feel free to unmute yourself
  • 03:40and ask questions.
  • 03:41Those who are on zoom.
  • 03:43Thank you.
  • 03:45So thank you Doctor Prasad and I wanted
  • 03:47to say that it's a particular honor
  • 03:50to follow Doctor Keshishian who spoke
  • 03:52in ground grand Grounds last week.
  • 03:54So Doctor Cashiering was one of
  • 03:56my mentors when I was an MDP.
  • 03:57She sitting here and he's actually the
  • 03:59first person that really told me to think
  • 04:01seriously about a career in pathology,
  • 04:03so perhaps he's listening today.
  • 04:04I hope so. I have nothing to disclose.
  • 04:08So today we have a diverse audience
  • 04:11and our department, so I'm going to
  • 04:13try and cover a lot of ground. My talk.
  • 04:16I'll start with an introduction to
  • 04:18the iron regulatory hormone hepcidin,
  • 04:20and talk about its dysregulation and
  • 04:23human genetic disorder of iron loading.
  • 04:25But I'll move on to the condition iron
  • 04:28refractory iron deficiency anemia, or Rita,
  • 04:30a genetic disorder of hepcidin, excess.
  • 04:34Then we'll move to new insights into
  • 04:36mechanisms of iron mobilization
  • 04:38from the liver.
  • 04:39From my laboratory work here and
  • 04:41finally some collaborative studies.
  • 04:43I've done it.
  • 04:44Yeah,
  • 04:45looking at the physiological consequences
  • 04:47of iron deficiency beyond anemia.
  • 04:50So let's start with iron regulation.
  • 04:53As this audience is well aware,
  • 04:56the maintenance of systemic iron
  • 04:58balance is really critical for health.
  • 05:002 little iron impairs of production
  • 05:02of many essential proteins,
  • 05:04most notable of course.
  • 05:05Hemoglobin leading to anemia,
  • 05:07and I'll remind you that iron
  • 05:09deficiency anemia is the most common
  • 05:12micronutrient deficiency worldwide.
  • 05:14About 80% of the global
  • 05:16population has low iron stores,
  • 05:19as estimated by The Who,
  • 05:21and about 30% of the global population
  • 05:23has overt anemia due to iron deficiency.
  • 05:27Conversely,
  • 05:27too much higher the problem for the body,
  • 05:29because iron causes oxidative damage
  • 05:32to tissues and this iron overload
  • 05:34can be acquired through chronic
  • 05:36blood transfusions and also in
  • 05:37a variety of genetic disorders,
  • 05:39including for example HFE
  • 05:41hereditary can chromatolysis,
  • 05:43as well as several iron loading remias.
  • 05:48Iron Physiology involves a complex
  • 05:50interplay between multiple organs.
  • 05:52Iron is absorbed in the duodenum and
  • 05:55it's transported into the Plaza, where it
  • 05:57finds the carrier protein transparent.
  • 05:59Iron Dentist delivered to the bone
  • 06:01marrow for red blood cell synthesis.
  • 06:03These red cells circulate and when they age,
  • 06:05they're phagocytosis by
  • 06:06macrophages in the spleen.
  • 06:08This allows the iron to be reclaimed
  • 06:11from hemoglobin and exported
  • 06:13back into circulation to support
  • 06:15further rounds of auricular crisis.
  • 06:17Iron, of course,
  • 06:18can also be used by other organs,
  • 06:20such as the heart, muscle,
  • 06:21pancreas and of course iron is needed
  • 06:23for the fetus during pregnancy.
  • 06:26The liver is the body's main iron Depot,
  • 06:29the main site of iron storage.
  • 06:33And daily we actually lose very
  • 06:35little iron from the body.
  • 06:37We have small losses from shedding of
  • 06:38the lining of the of the GI tract.
  • 06:40The Gu tracks the skin.
  • 06:42And of course menstruation and women.
  • 06:44But there's no known regulated mechanism
  • 06:47for iron excretion from the body.
  • 06:49As a result,
  • 06:51it's become clear that systemic
  • 06:53iron balance is regulated at the
  • 06:55level of intestinal absorption.
  • 06:57And so I thought,
  • 06:58inspired by Doctor Kashgari
  • 06:59and I show a little history.
  • 07:01So this is George H.
  • 07:02Whipple,
  • 07:03who was a pathologist,
  • 07:04actually a Yale undergraduate as well.
  • 07:07He's the whipple of Whipple's disease,
  • 07:08not procedure,
  • 07:09and he shared the 1934 Nobel Prize
  • 07:13for discovering it's concerning
  • 07:14liver therapy in cases of anemia.
  • 07:17This is a publication from his
  • 07:19group from 1943 in the Journal
  • 07:21of Experimental Medicine,
  • 07:21where they looked at radioactive iron
  • 07:24absorption by the gastrointestinal
  • 07:27tract of dogs.
  • 07:28And he made some summer lovations that
  • 07:31the gastrointestinal mucosa accepts
  • 07:33iron readily when the Iron Reserve
  • 07:36stores are depleted by chronic anemia,
  • 07:38but in a plethoric state when there is,
  • 07:40there is very little absorption
  • 07:42of iron and the body has no ready
  • 07:45means of disposing of surplus iron.
  • 07:47The body can protect itself against a
  • 07:51large accumulation of iron with the body,
  • 07:53which can cause damage to important organs,
  • 07:55as in hemochromatosis and
  • 07:57Mediterranean anemia.
  • 07:57The traditional name for a historical
  • 08:00name for beta thalassemia.
  • 08:02And the mechanism of this acceptance
  • 08:04or refusal of iron is of great interest
  • 08:07to physiologists and physicians.
  • 08:08So it took a long time for that
  • 08:11mechanism to be discovered,
  • 08:13but in the early 2000s it became
  • 08:15clear that the hormone called
  • 08:17hepcidin is the central regulator
  • 08:19of systemic iron balance.
  • 08:20So upside Nessa,
  • 08:22small peptide hormone produced
  • 08:23by hepatocytes you can detect it
  • 08:26in both blood and urine,
  • 08:28and hepcidin regulates iron balance
  • 08:30primarily by acting it to sites.
  • 08:32So upside and acts on enterocytes to
  • 08:35limit the absorption of dietary iron.
  • 08:37And hepcidin also acts on macrophages
  • 08:39to limit iron export from these cells.
  • 08:41This is the iron that has been
  • 08:44reclaimed from senescent red blood cells.
  • 08:47To have side and limits the
  • 08:49recycling of iron stores.
  • 08:50And molecular level have sided mediate
  • 08:53these effects by binding to fair portion,
  • 08:55which is a cellular iron exporter
  • 08:57present on the basolateral
  • 08:59surface of enterocytes and also on
  • 09:01the plasma membrane of macrophages.
  • 09:03Have side in binding to Fairport
  • 09:05and causes ferroportin,
  • 09:07endocytosis and degradation in lysosomes.
  • 09:10Additionally more recent work on
  • 09:12from the Group of elements has
  • 09:14shown that upside and actually
  • 09:15also includes the Fairport and
  • 09:17transporter blocking iron transport.
  • 09:21Have side an expression is modulated
  • 09:23in response to liver iron stores.
  • 09:25This is the basic regulation in the normal
  • 09:27state so that when body iron stores decrease,
  • 09:30have side and production is reduced and
  • 09:32this allows iron and iron absorption from
  • 09:35the intestine promoted as well as the iron
  • 09:38release from macrophage stores to proceed.
  • 09:41The net result here of course is to maintain
  • 09:43the level of iron in the circulation to
  • 09:46maintain the supply of iron for replaces,
  • 09:48the net effect being the prevention
  • 09:50of systemic iron deficiency.
  • 09:52And conversely,
  • 09:53when body iron stores increase liver
  • 09:55increases hepcidin production inhibiting
  • 09:57further dietary iron absorption and
  • 10:00inhibiting iron released from macrophages.
  • 10:06So genetic defects impacting the website
  • 10:09in Fairport and access underlie the major
  • 10:12inherited primary iron overload disorders.
  • 10:15There are five major disorders shown here.
  • 10:18I'm going to focus first on these.
  • 10:20These first three categories, SHFE related,
  • 10:23hemochromatosis juvenile hemochromatosis,
  • 10:25and TFR 2 related hemochromatosis.
  • 10:29So all of these disorders
  • 10:31are recessive disorders.
  • 10:33And characterized by similar patterns
  • 10:34of iron loading in the liver,
  • 10:36heart, and endocrine glands.
  • 10:38And the stylar iron accumulation
  • 10:41pattern is prankowl.
  • 10:43The gene products that are mutated
  • 10:45in these forms of hemochromatosis H,
  • 10:47Fe HJV or Hematoxylin.
  • 10:49HAMP, which is the hepcidin gene
  • 10:53itself or transparent receptor
  • 10:542A homologue of the transferrin
  • 10:56receptor on erythroid cells.
  • 10:58All of these gene products are are
  • 11:01acts in in parasites to promote
  • 11:03upside and transcription,
  • 11:05and I'll show you in a second the
  • 11:07other class of iron overload disorder
  • 11:10in this table are you Lisa disorders?
  • 11:13Between mutations in Fairport and itself
  • 11:15and there are two different forms.
  • 11:16They show autosomal dominant
  • 11:18inheritance and the features differ
  • 11:20depending upon the mutations or gain.
  • 11:21A function or loss of function mutations.
  • 11:24But I want to mostly focus on these non
  • 11:28Fairport and types of iron overload.
  • 11:31Because they all seem to converge on a
  • 11:33common signaling pathway in the liver,
  • 11:35so bone,
  • 11:35refrigerated protein or BMP SMAD
  • 11:37signaling is the major signaling pathway
  • 11:39promoting upside and transcription.
  • 11:41Perhaps sites in this pathway.
  • 11:44The BMP 6 ligand binds to receptor complex.
  • 11:47Promote the phosphorylation of
  • 11:49intracellular SMAD proteins which
  • 11:51translocates to the nucleus,
  • 11:52promoting the transcription of
  • 11:54upside and other BMP target genes.
  • 11:57The light interior BMP 6 interestingly
  • 11:59appears to be produced by liver
  • 12:01sinusoidal endothelial cells
  • 12:02in response to iron levels.
  • 12:04Although the mechanism by which
  • 12:06liver sinusoidal endothelial cells
  • 12:08sense iron to express the MP,
  • 12:10six is still under investigation.
  • 12:13Hema Jubelin but one of the gene
  • 12:16products mutated in juvenile
  • 12:17hemochromatosis is the GPI anchored
  • 12:19protein is the coreceptor for BMP's
  • 12:22and hepatocytes and hemogoblin
  • 12:23augment signaling to the BMP pathway.
  • 12:28HFE, the well known hereditary can
  • 12:31comatose this protein and transparent
  • 12:33receptor 2 are transmembrane proteins
  • 12:36that interact with the classic
  • 12:38transferrin receptor TNFR 1 to form
  • 12:40what is believed to be an iron sensing
  • 12:42complex that responds to levels of
  • 12:45transparent bound iron and circulation
  • 12:47and through and through the sensing,
  • 12:49modulate herbicide and transcription.
  • 12:52It's thought that perhaps these
  • 12:53proteins all participate in a
  • 12:56giant so-called super complex,
  • 12:57that that still remains to
  • 12:59be fully demonstrated,
  • 13:00but it seems likely that HFB and TFR 2
  • 13:03signaling also impact on the in peace man,
  • 13:06the B and PEACEMAN pathway.
  • 13:09So I'd like to move on now to from a
  • 13:12disorder disorders of hepcidin deficiency.
  • 13:15In the previous slide to disorders
  • 13:18of upside in excess.
  • 13:19So when I started my postdoc
  • 13:22with Nancy Andrews,
  • 13:23she marked Fleming and Matt
  • 13:25Henry at Children's Hospital.
  • 13:27Boston had collected DNA from a
  • 13:30number of children and never kindreds,
  • 13:33in which the children had iron
  • 13:35deficiency anemia that was
  • 13:37refractory to oral iron therapy.
  • 13:39And they called this condition a
  • 13:41red for this. For this phenotype.
  • 13:43The key clinical features were congenital,
  • 13:46hypochromic,
  • 13:46microcytic anemia and extremely low.
  • 13:50Erythrocyte mean corpuscular volume,
  • 13:51sometimes down into the 40s.
  • 13:53So extremely low.
  • 13:54Very low, transparent saturation.
  • 13:56A failure to respond to oral iron.
  • 14:00And a sluggish,
  • 14:01incomplete response to intravenous
  • 14:03or intramuscular iron and looking
  • 14:05at the pedigrees,
  • 14:06particularly this first pedigree from Turkey.
  • 14:08With consanguinity,
  • 14:09you can appreciate that transmission was
  • 14:12compatible with recessive inheritance.
  • 14:14Here's the typical blood smear from
  • 14:16one of the affected individuals,
  • 14:18showing classic signs of asphere
  • 14:21iron deficiency anemia.
  • 14:23So when I came to Nancy's lab and Eliza
  • 14:26assay to measure hepcidin levels in patients,
  • 14:30blood and urine had just become available
  • 14:33and looking at the phenotype individuals,
  • 14:35we were suspicious.
  • 14:36The phenotype of these individuals
  • 14:37and we were suspicious that they
  • 14:39had a defect in hepcidin regulation
  • 14:40and sure enough we found that have
  • 14:42side levels in these individuals
  • 14:44were inappropriately elevated.
  • 14:46So this of course explains the
  • 14:48pathophysiology of this disorder.
  • 14:50Normally an iron deficiency have
  • 14:51side and level should be low,
  • 14:53but in these in these individuals
  • 14:54who had decreased iron stores,
  • 14:56there have a side,
  • 14:57and it's paradoxically increased.
  • 14:59So it's explains both their failure to
  • 15:01respond to oral iron as well as their
  • 15:03failure to respond to intravenous
  • 15:05or intramuscular forms of iron.
  • 15:06Because these forms of iron require
  • 15:09processing by macrophages before
  • 15:10this iron can be exported into the
  • 15:12circulation for use in erythropoiesis.
  • 15:16So this is this was back in 2007
  • 15:21and before exome sequencing was,
  • 15:24it's cheap as it is today, and so I did.
  • 15:27Traditional linkage analysis,
  • 15:28mapping to map the phenotype
  • 15:30to region of chromosome 22.
  • 15:32This was a region of about 100
  • 15:34megabases many genes to sift through.
  • 15:37And as I was sifting through a particular
  • 15:39gene that came to our attention,
  • 15:41which is a gene called tempra 6,
  • 15:42also known as matriptase 2.
  • 15:45So this encodes a type 2
  • 15:48transmembrane serine protease.
  • 15:49Transmembrane serine protease
  • 15:516 is now it's official name.
  • 15:53That was known at that time to be
  • 15:56primarily expressed in the liver,
  • 15:57and had been found to be localized
  • 15:59to the plasma membrane when
  • 16:00overexpressed themselves at that time,
  • 16:02there were only two publications
  • 16:04on this protein.
  • 16:08Structurally, this protein consists
  • 16:09of a short intracellular region,
  • 16:11a transmembrane domain,
  • 16:13and a large extracellular
  • 16:14domain with several motifs,
  • 16:16including most notably AC,
  • 16:17terminal, serial, protease, domain.
  • 16:21What caught my eye was in the abstract
  • 16:24book for the 2007 ASH Annual meeting,
  • 16:26where the group of Ernie and
  • 16:28Bruce Boiler reported this.
  • 16:29Mouse munit temper 60 and new new mutant,
  • 16:32which is a mouse that you can see from
  • 16:35this picture, has hair on its head,
  • 16:36but it's all for the rest of his
  • 16:39body called the Mask Mutant.
  • 16:41The baldness relates to iron deficiency.
  • 16:43It's cured by feeding iron and they show
  • 16:46that these mice of course they they.
  • 16:47They map the temper 16 and the strain and
  • 16:49they showed that this was a recessive.
  • 16:51The phenotype where the mice had
  • 16:53iron deficiency anemia due to
  • 16:55impaired and absorption and looking
  • 16:56at the liver of these mice they had
  • 16:58elevated have side messenger RNA,
  • 17:00so obviously this was an excellent
  • 17:02candidate for the erythema type and I
  • 17:04went on to look at 10% as a candidate
  • 17:06in kinders with a Rita and we found a
  • 17:09number of mutations across the molecule,
  • 17:11classic,
  • 17:12frameshift mutations,
  • 17:13nonsense mutations and a
  • 17:14variety of missense mutations at
  • 17:17evolutionarily conserved residues.
  • 17:20So. Distinguishing Arita from other
  • 17:24required forms of iron deficiency anemia
  • 17:27cannot always be so straightforward.
  • 17:30I worked with Matt Heaney at
  • 17:32Children's Hospital Boston,
  • 17:33develop some diagnostic
  • 17:34algorithms for the disorder,
  • 17:36and I want to point out one of the
  • 17:37key aspects of these algorithms
  • 17:39is to consider how patients
  • 17:40respond to an oral iron challenge.
  • 17:42So you really want to look at how
  • 17:44their serum iron levels change after
  • 17:45you give them iron in the short term.
  • 17:48Short term,
  • 17:49after a fire administration
  • 17:50to help differentiate.
  • 17:51This is truly an absorptive.
  • 17:52Effect before proceeding.
  • 17:54Then at that time you know when genetic
  • 17:58testing was a little more expensive.
  • 18:00You know we we weren't going to think about
  • 18:02testing temper 6 immediately up front.
  • 18:04I think now with Exos,
  • 18:05a little
  • 18:05bit of a different story.
  • 18:08I also collaborated with Matt and Mark
  • 18:11Fleming to look at hepcidin levels
  • 18:14in patients with Arita and how they
  • 18:17compared to other patients with iron
  • 18:20refractory anemia that wasn't couldn't
  • 18:22be attributed to 10 per six mutation.
  • 18:24And indeed you know, as expected,
  • 18:26the hepcidin levels in patients with
  • 18:28temper 6 mutation based on our original
  • 18:30court where again seemed to be increased
  • 18:32but there was some overlap with patients
  • 18:34who did not have a temper 6 mutation.
  • 18:38And so we looked more closely
  • 18:40at various laboratory indices,
  • 18:41and you can see with these
  • 18:43receiver operating curves the red
  • 18:44curve here is to have side in.
  • 18:45This is a fairly good job of predicting
  • 18:48temper 6 mutation status in patients
  • 18:50with chronic iron refractory anemia,
  • 18:53but better indices turn out to be
  • 18:55indices where you normalize the
  • 18:57helpside into either the serum iron
  • 18:59or the the transparent saturation.
  • 19:03So of course I wanted to actually
  • 19:05figure out how society was working
  • 19:07to regulate upside in production.
  • 19:09The Group of Cleric and Michaela did
  • 19:12some beautiful invitro work showing
  • 19:14the temper 6 cleaves Hema, Julian,
  • 19:16the BMP coreceptor from the plasma membrane.
  • 19:19This is the gene product I showed
  • 19:20you a few minutes ago with one of
  • 19:22the genes that's mutated in juvenile
  • 19:25hemochromatosis and I went on and
  • 19:26now smodels to show that mice lacking
  • 19:28temper 6 show excess signaling through
  • 19:30the BMP pathway that is dependent
  • 19:32upon the presence of hemogoblin.
  • 19:39And then wait additional studies looking
  • 19:41at genetic loss of temper sticks and
  • 19:44other mouse models of clinical iron
  • 19:46overloads where iron overload is due to
  • 19:49have side insufficiency in particular,
  • 19:51predatory tosis due to HF mutation and also
  • 19:54non transfusion dependent beta thalassemia.
  • 19:57I won't get into the mechanism there
  • 19:59but let's just say briefly that inherent
  • 20:01in a congenital iron loading anemias
  • 20:03have signed news also low promoted
  • 20:05which promotes iron loading and our
  • 20:07group as well as the canvas shell.
  • 20:09Group demonstrated that indeed,
  • 20:10temper six loss is a way to raise
  • 20:14upside and limit iron loading in
  • 20:16in these iron loading disorders.
  • 20:19So approaches to modulate temperance
  • 20:21expression or under investigation.
  • 20:23So in addition to just doing the
  • 20:25classic knockout experiments,
  • 20:26groups have looked at small interfering RNA
  • 20:29S RNA formulated in lipid nanoparticles,
  • 20:31as well as antisense oligonucleotides.
  • 20:33The target temper 6 M RNA.
  • 20:36Here's here's a diagram showing the
  • 20:38antisense approach and the commentary
  • 20:40Rd on that paper and the idea here
  • 20:43of course is to cause degradation of
  • 20:45the temper 6 M RNA with these oligos.
  • 20:48Lose temper 6 from the plasma membrane
  • 20:50of these cells and now promote signaling
  • 20:52through these pathways to elevate have side.
  • 20:55Now I'll point out that currently
  • 20:57temper 6 antisense oligos,
  • 21:00specifically those that have been
  • 21:02caught conjugated to a liver specific
  • 21:04ligand and a settled Galactus demeanor.
  • 21:06Galac are in phase two clinical trials
  • 21:09for humans with pathological media.
  • 21:12I also want to point out that you know,
  • 21:14I showed you the complex CMP pathway earlier,
  • 21:17and while multiple proteins in that
  • 21:19pathways might be considered path
  • 21:21possibilities to modulate upside
  • 21:23and expression,
  • 21:24I want to point out that temper 6 is is
  • 21:26a particularly attractive target in my
  • 21:27mind because unlike many of the other
  • 21:29proteins I showed you in the BMP pathway,
  • 21:31this is a liver specific gene.
  • 21:34So hopefully you could reduce
  • 21:35a lot of off target effects.
  • 21:39So I'd like to move on now and
  • 21:41talk about new insights we've
  • 21:43made into the mechanisms of
  • 21:45iron mobilization and deliver.
  • 21:50So from what I've told you so far,
  • 21:51have sided therapies would seem like.
  • 21:55Reasonable approach to limit iron loading,
  • 21:58but one of the problems I see with those
  • 22:00types of therapies is they don't really
  • 22:02address the problem of iron loading.
  • 22:04It's already present once,
  • 22:05once in a dual mileage is loaded,
  • 22:07lowering raising their upside level is not
  • 22:09going to help eliminate the iron the iron.
  • 22:11This morning the body,
  • 22:13you know hereditary hemochromatosis sewers
  • 22:15are classically treated by phlebotomy.
  • 22:17Most patients can tolerate slotomania,
  • 22:19although it's definitely inconvenient
  • 22:21to have to be closed on a regular
  • 22:24basis throughout your life.
  • 22:26And although this is the classic therapy,
  • 22:28the mechanisms that promote
  • 22:29our immobilization are really
  • 22:31not well understood at all.
  • 22:33So this was an area I was
  • 22:35interested in exploring.
  • 22:36What are the mechanisms that regulate
  • 22:37the release of iron from the liver?
  • 22:41And I became more intrigued by this area.
  • 22:46When? With these this work from the
  • 22:49Group of Joe Mancius at Harvard and also
  • 22:53group from Novartis characterizing a
  • 22:55role of protein nuclear color receptor
  • 22:58coactivator 4 previously thought
  • 22:59to be a transcriptional regulator,
  • 23:01a new role in the regulation of ferritin,
  • 23:04trafficking within cells and
  • 23:06specifically in cancer cells.
  • 23:08These groups showed that NC A4 is a cargo
  • 23:12receptor that that shuttles the iron
  • 23:15transport complex ferritin to the lysosome.
  • 23:17We're fair to him, can be degraded,
  • 23:19and the iron can be released
  • 23:21into the cytoplasm,
  • 23:22potentially made available for
  • 23:24export cancel as well.
  • 23:26We were interested in this gene
  • 23:27actually was interested in gene
  • 23:28before these papers came up,
  • 23:30because I found it in some micro experiments.
  • 23:32Looking at, you know,
  • 23:33M RNA from livers of mice when iron
  • 23:36overload versus iron deficiency.
  • 23:38So Jay Lee,
  • 23:40who was a phenomenal Xpath
  • 23:41graduate student in my lab.
  • 23:43He graduated last year as well as Larissa.
  • 23:45Loads of Oscar Research Assistant
  • 23:47lab decided to really try and
  • 23:49define if insula forward had a role
  • 23:51in iron mobilization,
  • 23:53the mobilization of iron from ferritin
  • 23:55stores specifically in the liver.
  • 23:58So to do this,
  • 23:59we utilize chemically modified srna.
  • 24:02Since the galnet conjugated srna,
  • 24:04the targets have had ascites to lower NC
  • 24:074 expression to participates in vivo,
  • 24:10and this,
  • 24:10of course,
  • 24:11was after thoroughly validating
  • 24:13these sarnas and invitro.
  • 24:14Before we started the annual work.
  • 24:18So we looked at the responses of
  • 24:20animals that were treated with
  • 24:22either vehicle luciferase control
  • 24:24or end to a forward targeting
  • 24:26Sir and A and then subjected to a
  • 24:29large volume for botany and then
  • 24:31looking a week later to to see
  • 24:33their physiological responses.
  • 24:34So would the srna we see we
  • 24:37obtained excellent knocked out
  • 24:39of entry for in the liver.
  • 24:41And you can see that one week after
  • 24:44spodni mice treated with vehicle
  • 24:47control or luciferase control.
  • 24:49So to mark reduction hepatic Iron store,
  • 24:51the iron was exciting,
  • 24:53but in mice with Intuit for knockdown,
  • 24:55we didn't see that massive reduction
  • 24:57librarian stores and similarly
  • 24:59looking at ferritin protein levels,
  • 25:02we see that compared to the baseline
  • 25:04state mice treated with vehicle
  • 25:06luciferase controls showed marked
  • 25:08reduction to ferritin protein,
  • 25:09which is not seen in mice with
  • 25:11ensued 4 knocked down.
  • 25:13And we did further characterization
  • 25:14to just make sure that ensued.
  • 25:16Mice within two four knockdown
  • 25:18showed similar degrees of anemia,
  • 25:19transferrin,
  • 25:20saturation,
  • 25:20and have silence suppression
  • 25:22after full bodies.
  • 25:23So these other factors we couldn't
  • 25:25explain the difference in the liver
  • 25:27iron loading phenotype that we observed.
  • 25:29So and so if we're appears to be
  • 25:32limiting hepatic remobilization.
  • 25:34And this led us to question,
  • 25:35you know how is endogenous and two
  • 25:37for activity regulated and what's
  • 25:39the stimulus for iron mobilization?
  • 25:43So we then we just shifted to
  • 25:45work and hepatoma cells have the
  • 25:47cities are have three hepatoma
  • 25:49cells and we treated them first
  • 25:51with a chelator just proximity DFO.
  • 25:54And we found that this caused an
  • 25:57upregulation inside for a messenger RNA.
  • 26:00We realized in these experiments,
  • 26:02not only is DFO keliher,
  • 26:04but it's also a stabilizer of
  • 26:07hip hypoxia inducible factor.
  • 26:09And we treated hepatoma cells with
  • 26:11other chemicals known to stabilize
  • 26:13hip calcium chloride and demog
  • 26:16and observe similar upregulation
  • 26:18in institute for expression.
  • 26:20So you remember that the
  • 26:22poor little hydroxylases,
  • 26:23the HIF prolyl hydroxylases?
  • 26:26Or oxygen and iron dependent enzymes
  • 26:29that promote the degradation
  • 26:31of health HIF alpha subunits.
  • 26:33So in the normoxic and iron sufficient state.
  • 26:38HIF alpha subunits undergo post
  • 26:40translational modification and targeting
  • 26:42to the proteasome for degradation.
  • 26:44But, in the hypoxic or the iron,
  • 26:47sufficient insufficient state.
  • 26:49For example, in the setting of chelation.
  • 26:52Hips subunits alpha subunits are
  • 26:54available to translocate to the
  • 26:56nucleus where they can heterodyne
  • 26:58rise with the constitutive beta
  • 27:00subunit to criminal gene expression.
  • 27:02I'll remind you that they're both.
  • 27:04They're both the hip 1A and a hip 2A subunit.
  • 27:07So we wanted to investigate if
  • 27:09the answer for induction wouldn't,
  • 27:11if one HIF dependent process.
  • 27:13So using end to if we're knocked down.
  • 27:15Sorry using hip knockdown experiments
  • 27:19we were able to show first that in the
  • 27:21absence of knockdown we see a marked
  • 27:24induction of interferon chelation.
  • 27:26The treatment with the FL chelator
  • 27:28and this induction is abrogated
  • 27:31by knockdown of 51 or 52,
  • 27:34particularly the double combination together.
  • 27:37Jade went on to do some data mining.
  • 27:39We found a data set from the lava Peter
  • 27:42Ratcliffe in the UK who had done a
  • 27:45GMY chip seek experiment in hepatoma cells.
  • 27:48These are hep 3G hepatoma cells
  • 27:50under conditions.
  • 27:51Hypoxia and Jade was able to
  • 27:54identify in their data.
  • 27:56It hits one binding site actually hit
  • 27:58one hit two and HIF 1 beta binding site,
  • 28:01about 1.5 KB upstream of the
  • 28:04first exon and two A4.
  • 28:05So this LED us to a model in which
  • 28:08the hip one transcription factors
  • 28:10under HIP stabilizing conditions.
  • 28:12So either iron deficiency or hypoxia promote,
  • 28:15and so if we're transcription
  • 28:17increasing the supply of this protein
  • 28:19to participate in the ferritin,
  • 28:21not for the process described
  • 28:23by the Mancias group,
  • 28:25allowing ferret to be degraded.
  • 28:27An iron to be made available for use
  • 28:29and perhaps exported from the South.
  • 28:32So I think this has been relieved,
  • 28:33revealed a pathway with some
  • 28:36potential for our immobilization.
  • 28:37I think whether this could be capitalized
  • 28:39in iron disorders remains to be seen,
  • 28:41but could be very interesting
  • 28:42to investigate further.
  • 28:46So finally I'd like to move on to some
  • 28:50collaborative work I've done here,
  • 28:52switching now to thinking about
  • 28:54the physiological consequences,
  • 28:55iron deficiency beyond anemia,
  • 28:57and I'll talk about two collaborations.
  • 28:59One is looking at the relationship of
  • 29:01iron deficiency to platelet counts,
  • 29:03and the 2nd is the relationship of iron
  • 29:05deficiency to production of the hormone
  • 29:08fibroblast growth factor 23 or FGF 23.
  • 29:14So as as many in the
  • 29:16audience are probably aware,
  • 29:18iron deficiency media is often associated
  • 29:20with elevated platelet counts.
  • 29:22In humans. This is a agel observation.
  • 29:27I went back and looked at the
  • 29:28platelet counts and the patients with
  • 29:29a ride up and we've been focusing
  • 29:31on their red cell phenotypes.
  • 29:32Not thinking so much about their playlists,
  • 29:34but indeed if you look graph their
  • 29:36hemoglobin levels versus their platelets,
  • 29:38you see a really nice inverse
  • 29:41correlation between these parameters.
  • 29:45And so we wondered if we could
  • 29:47capitalize on the temper 6 knockout
  • 29:49model a mouse model of chronic iron
  • 29:51deficiency anemia to gain insight
  • 29:53into the underlying mechanism.
  • 29:54So you might just ask,
  • 29:55but why not just feed mice and you know
  • 29:57regular mice and iron deficient diet
  • 29:59and induce iron deficiency anemia.
  • 30:00It's actually quite technically
  • 30:02challenging to do that.
  • 30:03Mice have much such small daily iron needs,
  • 30:06and there's so much iron available
  • 30:07in their caging in their bedding.
  • 30:09It's very hard to conduct studies of
  • 30:13in which iron deficiency anemia is.
  • 30:15Consistently induced through
  • 30:16dietary means alone.
  • 30:18So This is why we're interested in
  • 30:20using the mouse model where we had a
  • 30:22genetic form of iron deficiency anemia.
  • 30:24We confirmed that the temper 6 knockout mice.
  • 30:27Of course,
  • 30:28as we move previously had low hemoglobin,
  • 30:31low MCV but also elevated platelets
  • 30:33and we also confirmed their
  • 30:35public plate elevation by facts.
  • 30:37This was actually quite important.
  • 30:38Those of you who remember your lab
  • 30:41medicine know that microsites so small
  • 30:43erythrocytes can easily miscounted
  • 30:45for platelets by cell counter.
  • 30:47This is a particular issue for
  • 30:49mice where the red cell MCV is
  • 30:51much smaller than the humans.
  • 30:53So we confirmed the plate elevation.
  • 30:55And here you can see the
  • 30:56peripheral blood smears,
  • 30:56and I think you can appreciate even
  • 30:58on the temper 6 knockouts where
  • 31:00it increased number of platelets.
  • 31:04So to make sure we could observe plate
  • 31:08elevation in mice with normal hepcidin
  • 31:10regulation we collaborated with Mark
  • 31:11Flemmings Group at Children's Hospital
  • 31:13boss and they were doing some studies
  • 31:15of iron deficiency and pregnancy.
  • 31:17So in pregnant mice that an iron
  • 31:19deficient diet they were able
  • 31:20to induce consistent anemia.
  • 31:22But of course that's a very difficult
  • 31:23experience for a long term experiment
  • 31:25because the mice will eventually give birth,
  • 31:26so it's it's not a practical
  • 31:28way to study this problem,
  • 31:29but it confirmed that this is
  • 31:31a not this played elevation.
  • 31:32We seen the temper 6 knockout might it's not.
  • 31:34It's not something specifically
  • 31:36related to their website and defect.
  • 31:38It's more general phenomena related in
  • 31:40some way to their iron deficiency anemia.
  • 31:42And oh, I wanted to point out, of course,
  • 31:44this is the collaboration with a group
  • 31:46of Diane Kraus 2 proposed excellent postdocs,
  • 31:48a former postdocs,
  • 31:50now Julianna Shaviv Trucchio
  • 31:52and Vanessa Scanlon.
  • 31:53Jade in my lab,
  • 31:54and Larissa in my lab as well.
  • 31:57So as many of you know,
  • 31:59Diane is very interested in hematopoiesis.
  • 32:02This is the classic hematopoiesis tree.
  • 32:05And here we have the megakaryocyte
  • 32:07erythroid progenitor cell.
  • 32:08So this is a cell that can decorate
  • 32:10down the megakaryocyte for the erythroid
  • 32:13lineage and Diane is very interesting
  • 32:16factors that control this fake decision.
  • 32:19So we hypothesized that the megakaryocyte
  • 32:21erythroid progenitor cell from iron
  • 32:24deficient mice would show a bias
  • 32:26towards the mid career site MK lineage.
  • 32:28Diane's lab has an excellent
  • 32:30assay to assess this,
  • 32:31so this is a colony forming assay to
  • 32:33assess the MK erythroid lineage potential
  • 32:35where the megakaryocyte erythroid peak,
  • 32:38which your cells or MP's or
  • 32:40isolated from mouse bone marrow
  • 32:42by facts grown with cytokines.
  • 32:45To promote the growth of
  • 32:47MK and erythroid progeny.
  • 32:49And after several days,
  • 32:50the colonies are fixed and stained
  • 32:52specifically for me to carry site
  • 32:53markers shown here in Green CD
  • 32:5541 and northward markers here.
  • 32:57City 71 the transferring receptor
  • 32:58shown in red so you can get
  • 33:01develop colonies that are MK only
  • 33:04erythroid only or a mix of the two.
  • 33:06And we found that compared to wild
  • 33:09type animals MEP's from temper 6
  • 33:11knockout mice showed an increased
  • 33:14percentage of colonies that
  • 33:16were only forming MK progeny.
  • 33:18So the MEP's from 10 per six knockout
  • 33:21mice were MK biased and in similar
  • 33:24studies we found that there was also
  • 33:27bias in mice would be dietary induced
  • 33:29our inefficiency anemia during pregnancy.
  • 33:34So the next question became,
  • 33:35does the low iron environment itself
  • 33:38promote the mercury site bias of the MEP?
  • 33:41So to address this we moved on to some
  • 33:43bone marrow transplantation experiments.
  • 33:46So in this experiment.
  • 33:47We took temper 6 wild type mice and
  • 33:50iron balance hosts or temper 6 knockout
  • 33:53mice and iron deficient host and they
  • 33:56were transplanted each with wild type.
  • 33:58Were not that bone marrow and I
  • 34:00want to remind you 10 per six is
  • 34:02not expressed in the bone marrow.
  • 34:03So, 12 weeks later,
  • 34:04we looked at the blood parameters
  • 34:06these animals and you can see that whenever
  • 34:08the we had a well typed recipient,
  • 34:10serum iron, blood, hemoglobin and plate
  • 34:12levels were all in the normal range.
  • 34:15The donor genotype for the
  • 34:17marriage didn't matter.
  • 34:18When we put knockout or wall table
  • 34:21mirror into knockout recipient.
  • 34:23They showed the animals showed
  • 34:25cerebral blood parameters consistent
  • 34:26with iron deficiency anemia,
  • 34:28and they showed elevation of platelets.
  • 34:31So we then used the Colony formation
  • 34:34assay to assess the MK erythroid
  • 34:37lineage potential of the MEP's and
  • 34:39you can see that when wildtype
  • 34:41mice were transplanted with wild
  • 34:42type were knockout marrow,
  • 34:44there was no significant difference.
  • 34:45The number of megakaryocyte
  • 34:48colonies produced.
  • 34:49However,
  • 34:49when the recipient was a knockout mouse,
  • 34:53we saw an increase in MK number of
  • 34:56the number of colonies that were
  • 34:59MP's that needed that yielded MK.
  • 35:01Only colonies to say that.
  • 35:04And a similar increase when wild type
  • 35:06mice was put into the knockout host.
  • 35:09So it was really the iron status of
  • 35:11the host was that was determined.
  • 35:12This commitment to the MK lineage
  • 35:15and in a number of further studies
  • 35:16that I'm not going to get into detail
  • 35:18here today we tried to get some
  • 35:20insight into the mechanism by which
  • 35:22this fake decision was occurring.
  • 35:24First,
  • 35:24we tried knocking down expression
  • 35:27of the transfer receptor,
  • 35:28one which mediates iron uptake,
  • 35:30but unfortunately that was that you know,
  • 35:33toxic to the cells,
  • 35:34so that that wasn't a viable.
  • 35:35Approach but in Human MP's we were
  • 35:38able to recapitulate this MK bias by
  • 35:42knocking down transparent receptor 2.
  • 35:44So this is the transformer receptor 2.
  • 35:46I just showed you that in the table
  • 35:48of hemochromatosis genes and it's
  • 35:49not only expressed in liver but
  • 35:50it also seems to play a role in
  • 35:53erythroid cells where it modulates
  • 35:54signaling through equation receptor.
  • 35:56So reducing expression of TFR 2
  • 35:58which is thought to be more of an
  • 36:01iron sensor rather than immediately
  • 36:04requiring uptake seem to modulate.
  • 36:06This MK bias.
  • 36:10For the last few minutes,
  • 36:11I want to talk about a collaboration we've
  • 36:14had with Jackie Fretz and Orthopedics
  • 36:16looking at emerging links between
  • 36:18iron deficiency and the hormone FGF.
  • 36:2023 fibroblast growth factor 23 so.
  • 36:24FGF 23. Is a hormone produced,
  • 36:28thought to produce classically
  • 36:29by osteocytes and bone,
  • 36:31and it plays a critical role in
  • 36:33skeletal health by regulating
  • 36:34the phosphate vitamin D axis,
  • 36:36circulating levels of FGF,
  • 36:3823 rise in patients with chronic
  • 36:40kidney disease, and this FGF.
  • 36:4223 elevation is associated with adverse
  • 36:45cardiovascular outcomes and all cause
  • 36:47mortality in patients both with
  • 36:49and without chronic kidney disease.
  • 36:51Whether or not FGF 23 is a direct mediator.
  • 36:54A biomarker I think is still under debate,
  • 36:57but what was interesting to us
  • 36:58and why others had approached me
  • 37:00about our model is the fact that
  • 37:03iron deficiency had been found to
  • 37:05correlate with FGF 23 elevation
  • 37:07in the circulation of both humans,
  • 37:10healthy humans and mouse models.
  • 37:13And so of course we wanted to turn
  • 37:15to the temperance model again to see
  • 37:16if we could use that as a tool here,
  • 37:18and we found that temper 6 knockout
  • 37:21mice compared to wild type where
  • 37:23heterozygous controlled so it increased
  • 37:25urine phosphate to creatinine ratios as
  • 37:27expected based on the known function
  • 37:30of FGF 23 and increased phosphate excretion.
  • 37:33And looking in their blood,
  • 37:34we saw level increased levels
  • 37:35of the active FGF 23 hormone,
  • 37:37as well as total FGF 23,
  • 37:40probably because it's a different.
  • 37:41A lot of apps say that analyzes.
  • 37:43Both inactive and active forms,
  • 37:45the hormone which undergoes cleavage.
  • 37:49So.
  • 37:49We thought we would be looking at
  • 37:52FGF 20 regulation of the bone.
  • 37:54But when we isolated bone mRNA
  • 37:57from bone cortex,
  • 37:59we actually found that FGF 23
  • 38:01elevation was not increased in
  • 38:03the temper of 6 knockout mice.
  • 38:05And we discovered 2 the better.
  • 38:07We clean the bone,
  • 38:08the clearer this cleaner that she
  • 38:09was all came showing no difference.
  • 38:11So it became very suspicious of
  • 38:12the Bone Arrow itself.
  • 38:13May be the source def.
  • 38:14Chapter 23.
  • 38:15Elevation iron deficiency anemia.
  • 38:17And indeed that's what we saw
  • 38:19when we looked at expression by
  • 38:21qPCR on the bone marrow.
  • 38:25So to get for more of a grip on what the cell
  • 38:28type was that produced was producing FGF,
  • 38:3123 we introduced an FGF 23 EGF reporter,
  • 38:34or little into the upper 6 mouse line,
  • 38:36so this is a well characterized
  • 38:38allele in which the the enhanced
  • 38:40green fluorescence protein, or egfp,
  • 38:43is knocked into the endogenous FGF 23
  • 38:46locus immediately after the start codon.
  • 38:48So this is a reporter allele that
  • 38:52also knocks out FGF 23 transcription
  • 38:55from the same allele.
  • 38:57And mice heterozygous for the supporter,
  • 38:59so the mice that have one functional FGF,
  • 39:0123 little only are known to maintain
  • 39:04normal hot phosphate balance.
  • 39:05So we bred the soul into the
  • 39:06temporal six months line and I won't
  • 39:08show you all the supporting data,
  • 39:09but basically wanted to prove that
  • 39:11temper 6 knockout mice carrying reporter
  • 39:13were still equally iron deficient.
  • 39:15Had equal degrees of anemia and retained
  • 39:17after you have 23 elevation in the plasma,
  • 39:19which they did.
  • 39:21One little a piece of data I'll show
  • 39:23you is inside is temper 6 knockout
  • 39:26mice also have elevated levels of
  • 39:28risk reports and we looked at various
  • 39:30lab parameters trying to see if we
  • 39:32found certain parameters that seemed
  • 39:33to correlate with FGF 23 elevation,
  • 39:35and in fact it was the erythropoietin level.
  • 39:37If we look across mice at different genotypes
  • 39:40that seemed to correlate best with FGF,
  • 39:4223 three levels in circulation,
  • 39:45and just hold that thought for now.
  • 39:48So we had a GFP reporter mouse.
  • 39:50We did flow cytometry.
  • 39:52The total bone marrow to try and
  • 39:54see if population and you can see
  • 39:56that in mice carrying the portfolio
  • 39:58both temper 6 knockout and temper 6
  • 40:00heterozygous with the reporter allele
  • 40:02heterozygous for the reporter level.
  • 40:03Just a very small fraction of
  • 40:05the population with GFP right?
  • 40:07But we did not see these small
  • 40:09fractions right.
  • 40:10Cells in my selected reporter.
  • 40:12This turned out to be less than .02% of
  • 40:15power cells and so Jade was very frustrated.
  • 40:17A bit heartbroken.
  • 40:18She thought these were going to be
  • 40:20incredibly difficult animals to work with.
  • 40:23So we we then took a look at the bone
  • 40:26marrow biopsies in these mice with
  • 40:29Jackie frats and here's confocal of.
  • 40:32Core biopsies after this very brief fixation,
  • 40:34you can see green fluorescent
  • 40:35throughout the Marina patterns,
  • 40:36suggesting localization to the vasculature.
  • 40:40So this led us to think more about our
  • 40:42flow cytometry and using a protocol
  • 40:45to enrich for endothelial cells.
  • 40:47We look specifically at GFP expression
  • 40:49within cells in the endothelial cell gate.
  • 40:52In mice,
  • 40:53the various temper 6 FGF 23 genotypes,
  • 40:57and we found that looking within the
  • 40:59endothelial cell gate mice that carry
  • 41:01the reporter allele showed a subset
  • 41:03of salt with breaking fluorescence,
  • 41:05which was not seen in my slacking
  • 41:08airport earlier.
  • 41:09And the percentage of cells in the
  • 41:11endothelial gate that were GFP bright
  • 41:13was higher in temperate 6 knockouts.
  • 41:15The iron deficiency type compared to
  • 41:17the non iron deficient heterozygous
  • 41:19controlled unit type.
  • 41:25So to gain further expression for
  • 41:28FGF 2323 elevation in expression
  • 41:30in bone marrow and Ophelia cells,
  • 41:32we mind a published data set from the lab.
  • 41:34David David Scadden in the study,
  • 41:37the author use single cell RNA seek of bone
  • 41:39marrow stromal cells from blastic mite sex,
  • 41:426 mice at steady state.
  • 41:44So these are normal mice.
  • 41:46Normal iron balance,
  • 41:47normal phosphate balance,
  • 41:48and in their study they were
  • 41:49able to identify 17 stromal cell
  • 41:51clusters and mining their data.
  • 41:53We found FGF 23.
  • 41:55Expression in the population they
  • 41:58defined as sinusoidal endothelial cells.
  • 42:01Looking more at the individual
  • 42:03single cell data,
  • 42:05you can see that the cells that
  • 42:07express FGF 23 also express,
  • 42:09and Ophelia cell markers,
  • 42:11Pecam 1 and amusin.
  • 42:13And they do not express classic bone markers.
  • 42:17These blue populations of the
  • 42:19osteon lineage populations,
  • 42:20which traditionally are thought to
  • 42:22be the populations producing FGF.
  • 42:2423,
  • 42:24And I'll point out one interesting
  • 42:26observation you found here,
  • 42:28is that erythropoietin express
  • 42:30receptor expression is also detected
  • 42:32in these sinusoidal endothelial cells,
  • 42:34which is why I mentioned the hypo
  • 42:36levels earlier in the correlation with FGF.
  • 42:3823 upregulation.
  • 42:42So to assess expression of the
  • 42:45FGF 23 reporter allele in the
  • 42:47context of tissue architecture
  • 42:48we employed immunohistochemistry,
  • 42:50good old immunohistochemistry with anti GFP
  • 42:52antibody and fixed bone marrow sections.
  • 42:55And you can see that mice carrying
  • 42:57the reporter allele showed stania
  • 42:59sign your little initial cells.
  • 43:02And the staining was not observed in mice
  • 43:04that do not carry the reporter allele.
  • 43:06The staining is more intense and the
  • 43:09iron deficient temper 6 knockout mice
  • 43:11than the heterozygous control mice.
  • 43:13And looking at lower power in one of the
  • 43:15temporal 6 knockouts with the reporter,
  • 43:18you can appreciate that this and
  • 43:19it still still still staining
  • 43:21extends throughout the bone marrow.
  • 43:25We also looked at other organs from
  • 43:27these animals and we detected GFP
  • 43:29expression rare cells of the thymus,
  • 43:31but not in in a variety of other organs,
  • 43:34including liver, spleen,
  • 43:35heart, muscle or kidney.
  • 43:36And I again want to give a special
  • 43:38shout out to Amos Brooks from
  • 43:40Yale Tissue pathology service,
  • 43:41who optimizes IHC staining which
  • 43:43which turned out to be really,
  • 43:46really beautiful. So.
  • 43:49We had shown temper 6 mice expressing
  • 43:53shave evidence of expressing FGF.
  • 43:5623 instinctual endothelial cells.
  • 43:57The catch here is that these
  • 43:59mice have upside and elevation,
  • 44:01so the question is now.
  • 44:04Our bone marrow,
  • 44:05signal hill and ethyl cells is cited FGF 23,
  • 44:07elevation in anemic might have
  • 44:09attacked outside of regulation.
  • 44:11So to test this we use the
  • 44:13FGF 23 Egfp reporter mice,
  • 44:15and this case these mice carried
  • 44:172 well tempered 6 wheels,
  • 44:19so they're not anemic.
  • 44:20They have normal iron status and we
  • 44:22subjected them to large volume colotomy
  • 44:25with intraperitoneal saline volume
  • 44:27replacement to induce acute anemia,
  • 44:29and you can see that 18 hours after flatter
  • 44:32you were successful inducing anemia.
  • 44:34People elevation and elevation of
  • 44:36plasma after you have 23 in the plasma.
  • 44:40And looking at their bone marrow
  • 44:41section at this time point,
  • 44:42you can see upregulation of FGF
  • 44:4423 and sinusoidal of the sorry of
  • 44:46the reporter allele in sinusoidal
  • 44:48endothelial cells of the phlebotomist
  • 44:50mice with the reporter compared to non
  • 44:53phlebotomist mice carrying reporter allele.
  • 44:56So this raises some questions.
  • 44:58Does does FGF 23 have a local
  • 45:00role in the bone marrow?
  • 45:02Is this a protective or
  • 45:05a pathological response?
  • 45:06There is a paper that came out in
  • 45:09blood from a Japanese group last
  • 45:11year that suggested that FGF 23
  • 45:13from a rifter blast is involved
  • 45:15in hematopoietic progenitor cell
  • 45:16mobilization for the bone marrow,
  • 45:18particularly,
  • 45:19this is in the context of induction of G.
  • 45:22CSF.
  • 45:24So exactly how their data fit together
  • 45:26with ours remains to be seen.
  • 45:28I I will say that in in their
  • 45:30paper they do also have expression
  • 45:32of FGF 23 detected in in flow,
  • 45:35sort of populations.
  • 45:36That would include the
  • 45:38sinusoidal endothelial cells,
  • 45:39although they don't specifically
  • 45:41look at that population.
  • 45:43So with that I just wanted to
  • 45:45acknowledge a huge number of people
  • 45:48that made this work possible.
  • 45:50It always takes the village
  • 45:51to do to do research,
  • 45:53starting with the original patients,
  • 45:55their family members,
  • 45:56and referring physicians at Yale.
  • 45:58I've mentioned Jade in my lab who
  • 46:00was a phenomenal PhD student,
  • 46:02Larissa and Outstanding Research assistant.
  • 46:05My mentor at Nancy who got
  • 46:07me started in the field.
  • 46:08I've mentioned collaborations with Mark,
  • 46:10Plumbing Group and Matheny at
  • 46:12Children's Hospital Boston.
  • 46:14Stefano Rebello was instrumental in
  • 46:16providing me with the Palace comic mice.
  • 46:19At Yale,
  • 46:19Jackie's been an excellent collaborator here,
  • 46:21as well as common Bergson,
  • 46:23endocrinology and then my main
  • 46:24collaborators have been the Yale
  • 46:26Cooperative Center of Excellence.
  • 46:27Hematology,
  • 46:28where I've been serving on the
  • 46:30steering committee Dianne,
  • 46:31Vanessa and Juliana,
  • 46:32and her in Diane's lab were absolutely
  • 46:35incredible for our studies.
  • 46:36Steffie Helenus Group has contributed.
  • 46:39Gene Hendrickson's group Pat Gallagher
  • 46:40and also some of the clinical
  • 46:42hematologists who referred me some very
  • 46:45interesting studies where I've been
  • 46:47looking at some exome data on some.
  • 46:49Never look phenotypes as well.
  • 46:51So with that I will stop and take questions.
  • 47:03Very nice. I have several
  • 47:07questions actually first.
  • 47:11So many different families here
  • 47:13in your planning and reaction
  • 47:16relationship with erythrocytes.
  • 47:18Tempress backup cameras 6.
  • 47:22That's also it appears the delivery
  • 47:25of Iron Company backer pitch.
  • 47:28So the Brotherhood islands
  • 47:29in the bone marrow.
  • 47:31Of course he contact with therapist
  • 47:33and order to survive and grow,
  • 47:35so could some of this effect and
  • 47:38ship complete the differentiation
  • 47:40via failure of the Riverside
  • 47:42support by the macrophage.
  • 47:44The other?
  • 47:44Maybe they need to sense
  • 47:45the iron in the back.
  • 47:50I think it's possible, but well,
  • 47:54you're thinking about specifically
  • 47:55upside and effect or just
  • 47:58a low iron effect. I think
  • 47:59you know about your knockout.
  • 48:03They would have trap. They would have.
  • 48:05They should have some relative.
  • 48:06They they may have some relative Miron
  • 48:09trapping in those in bone marrow macrophages,
  • 48:11yeah, but if there is we could that be a.
  • 48:15I remember in style selection.
  • 48:19The grip right precursor is not
  • 48:21in contact with that macro page.
  • 48:27You predicted it would shift it to
  • 48:30a plant. Spontaneous. By default.
  • 48:36Violence and everything.
  • 48:38No, I I will say that the effect of
  • 48:41hepcidin on bone marrow macrophages is
  • 48:43much less well studied than the effect
  • 48:45of macrophages in the spleen or liver.
  • 48:47You know, just people who
  • 48:48were studying mouse models.
  • 48:49It's somewhat easier to to be looking
  • 48:51at these assessments in the screen,
  • 48:52so I don't think it's been quite
  • 48:54as well characterized in mouse
  • 48:56models and have sided regulation.
  • 48:58Just regulation.
  • 49:01And then. Clearly the.
  • 49:05Most of these models show the
  • 49:07iron passing through the cell.
  • 49:09Either it's faster, it's it's
  • 49:12liberated in the auto light lights.
  • 49:16And then it is airborne
  • 49:17and puts it out right?
  • 49:19So we're talking about circulating iron.
  • 49:22To this cell is every cell have breakfast
  • 49:25control its internal iron levels,
  • 49:27and that must be a big important
  • 49:29thing in parasitosis control.
  • 49:31And now it's a bit
  • 49:33right. So so this is this is
  • 49:36another whole side of iron biology.
  • 49:40There's a great review called 2 to Tango,
  • 49:42written by Martina Buffet,
  • 49:43Baller and and several other leaders
  • 49:45in the field where you know upside and
  • 49:47regulations systemic are in regulation
  • 49:48but upside and acts on Fairport.
  • 49:50And of course which is expressed not
  • 49:51only in the cell types I showed you.
  • 49:53In fact, probably on most if
  • 49:55not all cell types in the body.
  • 49:57Cells also regulate iron status through
  • 50:00the iron regulatory protein system,
  • 50:02which stabilizes the messenger
  • 50:03RNA proteins that are involved
  • 50:05in iron transport into the cells.
  • 50:07The transferrin receptors normally
  • 50:09stabilized during iron deficiency
  • 50:11and during iron deficiency.
  • 50:13The translation of proteins involved
  • 50:16in iron exports, such as fair cordon,
  • 50:19is reduced so the cell have means
  • 50:21of compensating throughout.
  • 50:22Tosis is very interesting because the
  • 50:24transfer receptor is not behaving the
  • 50:25way you predict based on that system.
  • 50:27That's something actually asked
  • 50:29during his work talk last week,
  • 50:31I think, yeah.
  • 50:34That that's the big thing now
  • 50:37turn immunity. To regulate that.
  • 50:43Absolutely. Right?
  • 50:50Check chat, there's only one request that
  • 50:53people can hear questions.
  • 50:58Otherwise the ohh OK. The problem.
  • 51:09Yeah. Stick around.
  • 51:14There's a respect box here in
  • 51:16the body that are regulated.
  • 51:18This is level sheets, traumatic.
  • 51:21It's. My death was gross.
  • 51:26So, so I think this area has been explored.
  • 51:31Oh, sorry, so the question is how that
  • 51:34there are areas in the body where his
  • 51:36levels can change dramatically and our iron
  • 51:39levels in those areas regulated as well.
  • 51:42So the individual I know who's probably done
  • 51:44the most work in this area is Yatrik Shah,
  • 51:46Michigan, who's particularly focused
  • 51:47on the role of HIF one and hip two
  • 51:50in the intestinal cells where they
  • 51:53also appear to be modulating iron.
  • 51:55Of taking the cells in addition to
  • 51:57Fairport and so there is a more complex
  • 51:59story than what I told you today but,
  • 52:01but that's definitely an area under
  • 52:03active investigation as well.
  • 52:07I was thinking more like you.
  • 52:12Took my soul.
  • 52:16Of course.
  • 52:21Just in those.
  • 52:24Higher results.
  • 52:27Right?
  • 52:30I think it's it's certainly possible.
  • 52:31I'm not sure if anyone he's really looking.
  • 52:36So you know, truthfully we use an
  • 52:40old-fashioned Perls Prussian blue stain.
  • 52:42There certainly dies that people will
  • 52:44use for for self culture experiments.
  • 52:47Often we use expression
  • 52:49of the transfer receptor.
  • 52:50Messenger RNA is a simple
  • 52:52surrogate because that's so
  • 52:54responsive to the intracellular ion
  • 52:57concentrations of iron concentration.
  • 52:59But I you know that work may
  • 53:01be going on in this field.
  • 53:03I think I tend to gravitate
  • 53:05towards meetings where the focus
  • 53:07is on hematological disorders.
  • 53:08So so that I'm just probably
  • 53:10less familiar with that area now.
  • 53:16Affairs versus fairy these families.
  • 53:20So there are oxidases and reductases around.
  • 53:23Many of these transmembrane.
  • 53:24Passage steps that are also
  • 53:26part of the story. There.
  • 53:28There are many additional players.
  • 53:29These cartoons you know for iron
  • 53:31uptake that I've shipped friend
  • 53:33showed you yeah. I mean no.
  • 53:45OK, thank you so much for
  • 53:47the opportunity to present.
  • 53:52So.
  • 53:59Discovered.